Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure

Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery.

Reemplazo Mitral Transcatéter en Fallas de Bioprótesis

Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the aforementioned cases of bioprosthesis failure. However, unfortunately, we currently lack comprehensive analyses and large-scale randomized studies.

In this study, researchers conducted an analysis of 20 consecutive symptomatic patients who underwent TMViV replacement due to bioprosthesis failure.

Subjects with mitral annulus, annular calcification in the surgical bioprosthesis, or a transapical percutaneous valve were excluded.

The average age was 64 years, and 12 patients were women. More than half of the patients had diabetes, preserved renal function, an STS Score of 8.1%, and a EuroSCORE II of 9.2%.

Read also: Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2.

Before the procedure, ejection fraction was 44%, with a mean gradient of 13 mmHg. Bioprosthesis failure presented as stenosis with regurgitation in 12 patients, stenosis alone in 5 cases, and regurgitation alone in 2.

The procedure was successful in all patients, with no mortality, infarcton, or stroke. Three patients experienced major bleeding, one required automatic implantable cardioverter defibrillator (AICD), another needed dialysis, and the average hospital stay was 7 days.

Mortality at 30 days and one year was 1 patient and 2 patients, respectively.

Read also: Use of Apixaban and Post TAVR Valve Thrombosis.

After one year of follow-up, all patients were in functional classes I-II, with a gradient of 6 mmHg and an ejection fraction of 44%. All continued anticoagulation.

Conclusion

TMViM replacement with Meril Myval can be performed safely, with high technical success and low mortality at 30 days and one year.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using a Meril Myval Transcatheter Heart Valve.

Reference: Mullasari Ajit Sankardas, et al. Heart, Lung and Circulation (2023) , article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...